ambrisentan + placebo

ambrisentan + placebo refers to a specific treatment regimen used as the control arm in the CAPS-PAH (The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension) study. This Phase 4 clinical trial, led by Brigham and Women's Hospital, evaluated whether the addition of spironolactone to ambrisentan therapy improved exercise capacity in patients with pulmonary arterial hypertension (PAH). Ambrisentan is a selective endothelin type-A (ETA) receptor antagonist that works by blocking the effects of endothelin-1, a potent vasoconstrictor, on the pulmonary vasculature. By selectively targeting the ETA receptor, ambrisentan promotes vasodilation and inhibits the proliferation of vascular smooth muscle cells, thereby reducing pulmonary arterial pressure. In this trial arm, ambrisentan was administered alongside a placebo to serve as a comparator for the ambrisentan plus spironolactone combination.

Brand names

Letairis

Other names

ambrisentan + placebo-Brigham and Women's Hospital-pulmonary arterial hypertensionCAPS-PAH control arm